Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Avenzo Therapeutics

Avenzo Therapeutics

Avenzo Therapeutics is a developer of oncology therapies with a pipeline of oncology therapies.

: Private company
: 2022
: San Diego, CA, USUnited States

Avenzo Therapeutics' pipeline includes a selective CDK2 inhibitor and bispecific antibody-drug conjugates for solid tumors. The company is a developer of oncology therapies with a pipeline of oncology therapies.

The company's approach spans selective kinase inhibitors and bispecific antibody-drug conjugates for solid tumors. AVZO-021 is a selective CDK2 inhibitor for HR-positive breast cancer and ovarian cancer with elevated cyclin E expression. AVZO-1418 is a bispecific antibody-drug conjugate targeting EGFR and HER3 in non-small cell lung cancer, and AVZO-103 is a bispecific antibody-drug conjugate targeting Nectin4 and TROP2 in urothelial and breast cancers.

Similar Companies

Avotres

avotres.com

Rondo Therapeutics

rondotx.com

Advenchen Laboratories

advenchen.com

AdvanCell

advancell.com.au

Allorion Therapeutics

alloriontx.com

Abvc Biopharma

Avenge Bio

avengebio.com

A2 Biotherapeutics

a2bio.com

Innovo Therapeutics

Amphivena Therapeutics

Aeovian Pharmaceuticals

aeovian.com

Avstera Therapeutics

avstera.com

NextCure

nextcure.com

Avalo Therapeutics

avalotx.com

Adcentrx Therapeutics

adcentrx.com

Abbisko Therapeutics

abbisko.com

Nexo Therapeutics

nexotx.com

ADCendo

adcendo.com

Valink Therapeutics

valinktx.com

Ambagon Therapeutics

ambagontx.com

Quick Facts

Who are Avenzo Therapeutics' competitors?

Companies similar to Avenzo Therapeutics include Avotres, Rondo Therapeutics, Advenchen Laboratories and AdvanCell.

When was Avenzo Therapeutics founded?

Avenzo Therapeutics was founded in 2022.

Where is Avenzo Therapeutics' headquarters located?

Avenzo Therapeutics' headquarters is located in San Diego, CA, US.

How much disclosed funding has Avenzo Therapeutics raised?

As of Jun 1, 2026, Avenzo Therapeutics has disclosed funding of $842M (USD). Undisclosed round amounts are excluded.

Classification

Industry: Biotech
Biotechnology
Ownership: Private
Technology: Antibody Engineering
Kinase Inhibitors
Geographic Exposure: Americas United States

Model: Biotechnology
Clinical Stage Biopharma

Tags: Drug Development
Oncology

Also Known As: Avenzo Therapeutics, Inc.

Headquarters: 12707 High Bluff Drive, Suite 200
San Diego, CA, 92130
US

SEC CIK: 0001947742
EIN: 88-3737798

Industry: —Biotechnology Companies
YCOMBINATOR-INDUSTRY: —oncology